“…Specifically, current prevailing "amyloid cascade hypothesis" strongly believes that the misfolding and aggregation of intrinsically disordered proteins into highly ordered, β-structure-rich species (namely amyloids) is mainly responsible for a central pathogenic cause of PMDs [4][5][6] , e.g., the abnormal aggregation of Aβ, hIAPP, α-synuclein and hCT is associated with AD, T2D, PD, and MTC, respectively. Significant efforts and progresses have been made to develop different types of amyloid inhibitors (i.e., small organic molecules 7,8 , nanoparticles 9 , antibodies 10,11 , polymers 12 , and peptides 13,14 ) to prevent the production and aggregation of amyloid proteins. However, these inhibitors are mostly limited to single-target prevention strategies against specific amyloid proteins/aggregates, leading to no success for clinical cures of PMDs.…”